Author:
Elie C,Geay J F,Morcos M,Le Tourneau A,Girre V,Broët P,Marmey B,Chauvenet L,Audouin J,Pujade-Lauraine E,Camilleri-Broët S
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Alper Ö, Bergmann-Leitner ES, Bennet TA, Hacker NF, Stromberg K, Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375–1384
2. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4): 31–39
3. Baekelandt M, Kristensen GB, Trope CG, Nesland JM, Holm R (1999) Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res 19: 4469–4474
4. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams AR, Lessells AM, Macleod KG, Smyth JF, Miller WR (1996) The prognostic value of epiodermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73: 301–306
5. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292–4302
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献